Evidence map›Paper›PMID 40365392›Full record

ArticleACS medicinal chemistry letters2025

Discovery of

Sara Rossi, Luca Pozzetti, Gabriele Carullo, Maria Dichiara, Stefania Butini, Marco Radi, Anna Ramunno, Chiara Terrosi, Giovanni Barra, Rita Berisio and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sara RossiDepartment of Food and Drug, University of Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy.
Luca PozzettiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Gabriele CarulloDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID https://orcid.org/0000-0002-1619-3295
Maria DichiaraDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
Stefania ButiniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID https://orcid.org/0000-0002-8471-0880
Marco RadiDepartment of Food and Drug, University of Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy.ORCID https://orcid.org/0000-0002-0874-6697
Anna RamunnoDepartment of Pharmacy, University of Salerno, Via G. Paolo II 132, 84084 Fisciano, SA, Italy.ORCID https://orcid.org/0000-0003-1089-2439
Chiara TerrosiDepartment of Medical Biotechnologies, University of Siena and Siena University Hospital, V.le Bracci 1, 53100 Siena, Italy.
Giovanni BarraInstitute of Biostructure and Bioimaging, Research National Council, CNR, Via Pietro Castellino 111, 80131 Napoli, Italy.
Rita BerisioInstitute of Biostructure and Bioimaging, Research National Council, CNR, Via Pietro Castellino 111, 80131 Napoli, Italy.ORCID https://orcid.org/0000-0001-5025-6483
Sandra GemmaDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID https://orcid.org/0000-0002-8313-2417
Maria Grazia CusiDepartment of Medical Biotechnologies, University of Siena and Siena University Hospital, V.le Bracci 1, 53100 Siena, Italy.
Giuseppe CampianiDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.ORCID https://orcid.org/0000-0001-5295-9529

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After the global eradication of smallpox has occurred, Monkeypox virus (MPXV) is nowadays the most significant pathogen affecting humans among orthopoxviruses. The recent growing number of cases worldwide is drawing researchers' attention, prompting for the discovery of new antivirals with optimized synthetic protocols and enhanced efficacy. To date tecovirimat, targeting the membrane-anchored phospholipase p37, is the only drug specifically approved for the treatment of MPXV. In an effort to develop inhibitors with more accessible synthetic protocols and broaden the poorly explored structure-activity relationship (SAR) studies, a new library of tecovirimat analogues has been designed and synthesized. The resulting compounds have been tested in phenotypic assays to evaluate their antiviral inhibitory properties. Spirovirimat (

Identifiers

PMID40365392
PMCPMC12067134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.